PDCD1 and cancer: For immunotherapy, several clinical studies had demonstrated that combination therapy of anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies and anti-programmed cell death protein-1 (PD-1) antibodies could significantly improve oncological outcomes for some hard-to-treat cancer types.